Effect of the look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes

J Bruce Redmon, Alain G Bertoni, Stephanie Connelly, Patricia A Feeney, Stephen P Glasser, Henry Glick, Frank Greenway, Louise A Hesson, Michael S Lawlor, Maria Montez, Brenda Montgomery, Look AHEAD Research Group, J Bruce Redmon, Alain G Bertoni, Stephanie Connelly, Patricia A Feeney, Stephen P Glasser, Henry Glick, Frank Greenway, Louise A Hesson, Michael S Lawlor, Maria Montez, Brenda Montgomery, Look AHEAD Research Group

Abstract

Objective: To examine the effect of a lifestyle intervention to produce weight loss and increased physical fitness on use and cost of medications to treat cardiovascular disease (CVD) risk factors in people with type 2 diabetes.

Research design and methods: Look AHEAD is a multicenter randomized controlled trial of 5,145 overweight or obese individuals with type 2 diabetes, aged 45-76 years. An intensive lifestyle intervention (ILI) involving group and individual meetings to achieve and maintain weight loss through decreased caloric intake and increased physical activity was compared with a diabetes support and education (DSE) condition. Medications prescribed to treat diabetes, hypertension, and hyperlipidemia were compared at baseline and 1 year. Medication costs were conservatively estimated using prices from a national online pharmacy.

Results: Participants randomized to an ILI had significantly greater improvements in CVD risk parameters and reduced medication use and cost compared with those assigned to DSE. At 1 year, average number of medications prescribed to treat CVD risk factors was 3.1 +/- 1.8 for the ILI group and 3.6 +/- 1.8 for the DSE group (P < 0.0001), with estimated total monthly medication costs of $143 and $173, respectively (P < 0.0001). DSE participants meeting optimal care goals at 1 year were taking an average of 3.8 +/- 1.6 medications at an estimated cost of $194/month. ILI participants at optimal care required fewer medications (3.2 +/- 1.7) at lower cost ($154/month) (P < 0.001).

Conclusions: At 1 year, ILI significantly improved CVD risk factors, while at the same time reduced medication use and cost. Continued intervention and follow-up will determine whether these changes are maintained and reduce cardiovascular risk.

Trial registration: ClinicalTrials.gov NCT00017953.

References

    1. Stewart ST, Cutler DM, Rosen AB: Forecasting the effects of obesity and smoking on U.S. life expectancy. N Engl J Med 2009;361:2252–2260
    1. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ: Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007;30:162–172
    1. Global Guideline for Type 2 Diabetes [article online], 2005. Available from . Accessed August 2008
    1. Saydah SH, Fradkin J, Cowie CC: Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335–342
    1. American Diabetes Association. Standards of medical care in diabetes, 2008. Diabetes Care 2008;31(Suppl. 1):S12–S54
    1. Hood RC: It can be done. Diabetes Care 2003;26:3359–3360
    1. Turner RC, Cull CA, Frighi V, Holman RR: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005–2012
    1. Winocour PH: Effective diabetes care: a need for realistic targets. BMJ 2002;324:1577–1580
    1. Cramer JA: A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218–1224
    1. Huang ES, Brown SE, Ewigman BG, Foley EC, Meltzer DO: Patient perceptions of quality of life with diabetes-related complications and treatments. Diabetes Care 2007;30:2478–2483
    1. Colllins RW, Anderson JW: Medication cost savings associated with weight loss for obese non-insulin-dependent diabetic men and women. Prev Med 1995;24:369–374
    1. Wolf AM, Conaway MR, Crowther JQ, Hazen KY, Nadler JL, Oneida B, Bovbjerg VE: Translating lifestyle intervention to practice in obese patients with type 2 diabetes. Diabetes Care l 2004;27:1570–1576
    1. Anderson JW, Conley SB, Nicholas AS: One hundred-pound eeight losses with an intensive behavorial program: changes in risk factors in 118 patients with long-term follow-up. Am J Clin Nutr 2007;86:301–307
    1. Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, Clark JM, Curtis JM, Espeland MA, Foreyt JP, Graves K, Haffner SM, Harrison B, Hill JO, Horton ES, Jakicic J, Jeffery RW, Johnson KC, Kahn S, Kelley DE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montgomery B, Nathan DM, Patricio J, Peters A, Redmon JB, Reeves RS, Ryan DH, Safford M, Van Dorsten B, Wadden TA, Wagenknecht L, Wesche-Thobaben J, Wing RR, Yanovski SZ: Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care 2007;30:1374–1383
    1. Bray G, Gregg E, Haffner S, Pi-Sunyer XF, WagenKnecht LE, Walkup M, Wing R: Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in Diabetes) study. Diab Vasc Dis Res 2006;3:202–215
    1. Ryan DH, Espeland MA, Foster GD, Haffner SM, Hubbard VS, Johnson KC, Kahn SE, Knowler WC, Yanovski SZ: Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 2003;24:610–628
    1. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: the evidence report: National Institutes of Health. Obes Res 1998;6(Suppl. 2):51S–209S
    1. Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WJ, Robbins DC, Howard BV: Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the Strong Heart Study. Diabetes Care 2003;26:16–23
    1. Franco OH, Steyerberg EW, Hu FB, Mackenbach J, Nusselder W: Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med 2007;167:1145–1151
    1. Davidson MB: Triple therapy: definitions, application, and treating to target. Diabetes Care 2004;27:1834–1835
    1. Hemmelgarn B, Levesque LE, Suissa S: Anti-diabetic drug use and the risk of motor vehicle crash in the elderly. Can J Clin Pharmacol 2006;13:e112–e120
    1. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC: Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716–1730
    1. Gerstein HC, Miller ME, Byington RP, Goff DC, Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Jr, Probstfield JL, Simons-Morton DG, Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–2559
    1. American Diabetes Associations. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596–615

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe